Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-05-08
2007-05-08
Ewoldt, G. R. (Department: 1644)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S387300, C530S388250, C424S134100, C424S135100, C424S145100
Reexamination Certificate
active
10344514
ABSTRACT:
The present invention provides a human antibody against blood coagulation factor VIII (hereinafter also referred to as “FVIII”) and an antibody fragment that binds to human FVIII and specifically inhibits the coagulation activity of human FVIII. ScFv display phage libraries, prepared by using scFv DNAs constructed by random combinations of immunoglobulin VH chain genes and VL chain genes from lymphocytes from hemophilia A patients, is reacted with FVIII immobilized to a solid phase via anti-FVIII monoclonal antibody, and scFv clones capable of binding to FVIII are cloned to reveal VH and VL chains of FVIII-specific antibody.
REFERENCES:
patent: 5693762 (1997-12-01), Queen et al.
patent: 2838166 (1998-10-01), None
patent: WO 01/04269 (2001-01-01), None
patent: WO 01/62907 (2001-08-01), None
Gavilondo et al., “Antibody engineering at the millennium” (2000) Biotechniques, 29;128-145.
Hu et al. “Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts” (1996) Cancer Research, 56:3055-3061.
Janeway et al., Immunobiology, Third edition, Garland Publishing Inc., (1997) 3:7-3.9).
van den Brink, Edward et al., BLOOD, vol. 97, No. 4, pp. 966-972, (2001).
van den Brink, Edward N. et al., BLOOD, vol. 95, No. 2, pp. 558-563, (2000).
van den Brink, Edward N. et al., BLOOD, vol. 96, No. 2, pp. 540-545, (2000).
Victor, Kimberly D. et al., Eur. J. Immunol., vol. 22, pp. 2231 to 2236, (1992).
Marc G. Jacquemin et al.; BLOOD, vol. 92, No. 2, Jul. 15, 1998, pp. 496-506.
Marc Jacquemin et al.; Blood; Jan. 1, 2000, vol. 95, No. 1, pp. 156-163.
James D. Marks et al.; J. Mol. Biol., 1991, No. 222, pp. 581-597.
W.H. Ouehand et al.; The International Congress on Thrombosis and Hemostasis, Jun. 1995 (Israel) (1995, ISTH).
J. Davis et al.; The International Congress on Thrombosis and Hemostasis, Jun. 1997.
John F. Healey et al.; Blood, vol. 92, No. 10, Nov. 15, 1998, pp. 3701-3709.
F.R. Rosendaal et al.; British Journal of Haematology, 1990, No. 75, pp. 525-530.
Ted Koster et al.; The Lancet; vol. 345, Jan. 21, 1995, pp. 152-155.
Frits R. Rosendaal; Seminars in Hematology, vol. 34, No. 3, Jul. 1997, pp. 171-187.
Maura Mhic Iomhair et al.; Thrombosis Research, vol. 87, No. 4, pp. 359-362, 1997.
Nakashima Toshihiro
Yuguchi Masato
Ewoldt G. R.
Juridical Foundation The Chemo-Sero-Therapeutic Research Institu
Szperka Michale
LandOfFree
Human-type anti-blood coagulation factor VIII antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human-type anti-blood coagulation factor VIII antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human-type anti-blood coagulation factor VIII antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3733759